News Kisqali set for approval - but likely to hit same NICE obsta... Concerns that NICE will reject Kisqali like it did Ibrance.
News Novartis' canakinumab cuts risk for heart attack survivors Novartis to discuss canakinumab results with regulators.
News Novartis next generation eye drug outperforms Eylea Brolucizumab could offer quarterly dosing schedule.
Views & Analysis Verily, Novartis join fund to support Europe’s biotech entre... New $300m fund aimed at helping European biotechs to grow, providing alternative to an IPO or 'generally suboptimal' licensing or big pharma acquisition
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
